ARVN.NASDAQArvinas, INC
DEF 14A: Arvinas, Inc. Announces Details for 2024 Annual Stockholders Meeting
Sentiment:
Proxy Statement
Arvinas, Inc. has scheduled its 2024 Annual Meeting of Stockholders as a virtual event on May 29, 2024, to vote on director elections, executive compensation, and auditor ratification.
Summary
- Arvinas, Inc. will hold its 2024 Annual Meeting of Stockholders virtually on May 29, 2024, at 8:30 a.m. Eastern Time.
- Stockholders of record as of April 1, 2024, are eligible to vote on the election of three Class III directors, an advisory vote on executive compensation, and the ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
- The Board recommends voting FOR the election of Edward Kennedy, Jr., Everett Cunningham, and Briggs Morrison, M.D. as Class III directors.
- The Board also recommends voting FOR the advisory vote on executive compensation and FOR the ratification of Deloitte & Touche LLP.
- Proxy materials are available online, and stockholders can request printed copies.
- The company's board of directors consists of ten members divided into three classes with staggered three-year terms.
- Wendy Dixon, Ph.D., will not be standing for re-election as a Class III director at the Annual Meeting.
- Following the Annual Meeting subject to approval of this proposal, our board of directors will consist of nine members.
Sentiment
Score: 7
Explanation: The document is a standard proxy statement, which is generally neutral in tone. The positive aspects include the recommendation to vote for the proposals and the convenience of the virtual meeting. The negative aspects are the risks mentioned in the 2023 Annual Report.
Positives
- The company is providing stockholders with convenient access to proxy materials via the internet, reducing paper and mailing costs.
- The virtual meeting format is designed to enhance stockholder access and participation from any location.
- The board of directors has nominated experienced individuals for election as Class III directors.
- The board recommends voting FOR the advisory vote on executive compensation, indicating confidence in the company's executive compensation programs.
Negatives
- Wendy Dixon, Ph.D., will not be standing for re-election as a Class III director at the Annual Meeting.
- Following the Annual Meeting subject to approval of this proposal, our board of directors will consist of nine members.
Risks
- The document mentions risks described under 'Risk Factors' in the company's 2023 Annual Report, indicating potential challenges the company faces.
- The document mentions that Codiak BioSciences, Inc., where Ms. Bain previously served as Chief Financial Officer, filed a voluntary petition for relief under Chapter 11 of the U.S. Bankruptcy Code in March 2023.
Future Outlook
The company plans to announce preliminary voting results at the Annual Meeting and will publish final results in a Current Report on Form 8-K to be filed with the SEC within four business days following the Annual Meeting.
Management Comments
- The board of directors recommends that you vote FOR each of the Class III director nominees (Proposal 1), and FOR each of Proposals 2 and 3.
- We believe that hosting a virtual meeting will enable greater stockholder attendance and participation from any location around the world.
- Your vote is very important. Whether or not you plan to attend the Annual Meeting in person, we urge you to take the time to vote your shares.
Industry Context
Arvinas is operating in the competitive biopharmaceutical industry, focusing on the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company's approach with PROTAC targeted protein degraders is innovative and could potentially address previously undruggable targets.
Comparison to Industry Standards
- The peer group used for executive compensation benchmarking includes companies like Alector, Intellia Therapeutics, and Karuna Therapeutics, indicating that Arvinas benchmarks against other pre-commercial, later-stage biopharmaceutical companies.
- The compensation committee uses a comparative framework to assess the named executive officers total compensation mix, but does not have a pre-established policy for allocating total compensation.
- The compensation committee engaged Aons Human Capital Solutions Practice (formerly Radford) as its compensation consultant during 2023.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Financial Officer | Sean Cassidy | Randy Teel, Ph.D. (interim) | February 2024 | Cassidy's departure |
| Chief Medical Officer | Ronald Peck, M.D. | Noah Berkowitz, M.D., Ph.D. | March 2024 | Peck's departure |
| Class III director | Wendy Dixon, Ph.D. | N/A | May 29, 2024 | Dixon will not be standing for re-election |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Board Leadership Structure | The roles of chairperson of the board and chief executive officer have been combined, with John Houston, Ph.D. serving in both roles. Briggs Morrison, M.D. was appointed as lead independent director. | June 2023 | This structure aims to foster clear accountability, effective decision-making, and alignment of corporate strategy. |
| Compensation Committee | Following the Annual Meeting, we expect that our board of directors will reconstitute the compensation committee, such that the committee will comprise Laurie Smaldone Alsup, M.D., Everett Cunningham and John Young, with Mr. Young as the chair of the compensation committee. | Following the Annual Meeting | This structure aims to foster clear accountability, effective decision-making, and alignment of corporate strategy. |
Related Party Transactions
- In November 2023, Arvinas entered into a securities purchase agreement with EcoR1 Capital, LLC and Avidity Partners Management LP, who beneficially owned greater than 5% of Arvinas' voting securities.
Stakeholder Impact
- Shareholders are being asked to vote on key proposals that will impact the company's governance and executive compensation.
- Employees are impacted by the company's compensation and benefits policies, as well as its commitment to diversity, equity, and inclusion.
- The company's performance and strategic decisions ultimately impact patients who may benefit from its therapies.
Next Steps
- Stockholders are encouraged to vote their shares prior to the Annual Meeting.
- The company will announce preliminary voting results at the Annual Meeting and publish final results in a Current Report on Form 8-K.
Key Dates
| Date | Description |
|---|---|
| 2013-07 | Timothy Shannon, M.D. served as the Chairperson and a member of our board of directors from July 2013 to June 2023. |
| 2014-01 | Mr. Kennedy is currently Partner and Member of the Health Care and Life Sciences practice of Epstein Becker & Green, P.C., a national law firm, where he counsels healthcare companies on the legal, reimbursement, coding and coverage issues facing providers, payers and the life sciences industry, since January 2014. |
| 2015-06 | Dr. Morrison has also served as Executive Partner at MPM Capital, Inc. since June 2015. |
| 2015-09 | Dr. Houston served in positions of increasing responsibility at The Bristol-Myers Squibb Company, a biopharmaceutical company, most recently as Senior Vice President, Head of Specialty Discovery from September 2015 to August 2016. |
| 2016-08 | Dr. Morrison was a member of our Scientific Advisory Board from August 2016 to June 2018. |
| 2017-09 | John Houston, Ph.D., has served as a member of our board of directors and as our President and Chief Executive Officer since September 2017. |
| 2018-07 | Edward Kennedy, Jr. has served as a member of our board of directors since July 2018. |
| 2018-09 | In September 2018, our board of directors adopted and our stockholders approve d 2018 Plan, which became effective immediately prior to our IPO. |
| 2018-06 | Briggs Morrison, M.D., has served as a member of our board of directors since June 2018 and lead independent director since June 2023. |
| 2019-07 | Leslie V. Norwalk Esq., has served as a member of our board of directors since July 2019. |
| 2020-06 | Linda Bain has served as a member of our board of directors since June 2020. |
| 2020-01 | From January 2020 to through 2023, Dr. Berkowitz was Senior Vice President Hematology Development at Bristol-Myers Squibb, where his teams were responsible for multiple global regulatory approvals for small molecules, biologics and cell therapies. |
| 2022-08 | John Young has served as a member of our board of directors since August 2022. |
| 2022-12 | Everett Cunningham has served as a member of our board of directors since December 2022. |
| 2023-03 | We established a science and technology committee in March 2023. |
| 2023-06 | Sunil Agarwal, M.D., has served as a member of our board of directors since June 2023. |
| 2023-06 | Following the 2023 annual meeting of stockholders in June 2023, or the 2023 Annual Meeting, upon Dr. Shannons cessation of tenure as chairperson and member of our board of directors, our board of directors has determined that the roles of chairperson of the board of directors and chief executive officer should be combined. |
| 2023-04 | Dr. Morrison has served as Chief Executive Officer of Crossbow Therapeutics, Inc., a biotechnology company, since April 2023. |
| 2023-05 | Ms. Bain has served as Chief Operating Officer and Chief Financial Officer for Mariana Oncology, Inc., a radiopharmaceutical company, since May 2023. |
| 2023-02 | In February 2023 , the board of directors, upon recommendation by the compensation committee, approved annual grants of stock options and restricted stock units, or RSUs, under the 2018 Plan to our Chief Executive Officer, and the compensation committee approved grants of stock options and RSUs under the 2018 Plan to our other named executive officers. |
| 2023-11 | Oversubscribed private investment in public equity transaction executed in November 2023 for $350 million, with participation from existing and new institutional. |
| 2024-01 | Dr. Smaldone Alsup has served as Senior Vice President, Regulatory Science and Practical Lead of SSI Strategy Holdings LLC, a consulting firm that supports the needs of the medical affairs, pharmacovigilance, and clinical development functions within life science companies, or SSI Strategy, since January 2024. |
| 2024-02 | Randy Teel, Ph.D., has served as our interim Chief Financial Officer and Treasurer since February 2024. |
| 2024-03 | Noah Berkowitz, M.D., Ph.D., has served as our Chief Medical Officer, since March 2024. |
| 2024-03 | In March 2024, our board of directors undertook a review of the independence of each director. |
| 2024-04-01 | Record date for the Annual Meeting. |
| 2024-04-16 | On or about April 16, 2024, we will begin mailing a Notice of Internet Availability of Proxy Materials, or Notice, to all stockholders of record on our books at the close of business on April 1, 2024, the record date for the Annual Meeting, and we will post our proxy materials on the website referenced in the Notice. |
| 2024-04-16 | The Notice regarding our proxy materials, including this proxy statement and our 2023 Annual Report, is being mailed to stockholders on or about April 16, 2024. |
| 2024-05-29 | Date of the 2024 Annual Meeting of Stockholders. |
| 2024-12-17 | Deadline for stockholders to submit proposals for inclusion in the 2025 proxy statement. |
| 2025-01-29 | Earliest date for stockholders to submit proposals to be brought before the 2025 annual meeting. |
| 2025-02-28 | Latest date for stockholders to submit proposals to be brought before the 2025 annual meeting. |
Keywords
Annual Meeting, Proxy Statement, Stockholders, Board of Directors, Director Election, Executive Compensation, Deloitte & Touche LLP, Corporate Governance, Arvinas
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.